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ABSTRACT
The coronavirus disease 2019 (covid-19) pandemic has caused a public health emergency worldwide. 
Risk, severity and mortality of the disease have been associated with non-communicable chronic 
diseases, such as diabetes mellitus. Accumulated evidence has caused great concern in countries 
with high prevalence of this morbidity, such as Brazil. This text shows the picture of diabetes in 
Brazil, followed by epidemiological data and explanatory hypothesis for the association between 
diabetes and covid-19. We emphasized how the burden of these two morbidities in a middle-
income country has aggravated this pandemic scenario. The comprehension of this association 
and biological plausibility may help face this pandemic and future challenges. 
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INTRODUCTION
On March 11th, 2020, the World Health Organization declared the outbreak caused by the 
novel coronavirus (SARS-CoV-2), the coronavirus disease 2019 (covid-19), as pandemic. The 
disease is responsible for more than 180 thousand deaths worldwide, with approximately 
4,000 occurring in Brazil until the end of April 2020 (https://coronavirus.saude.gov.br/). 
Fatality rates have varied among countries depending on factors that influence both 
numbers of confirmed cases and registered deaths, as well as the proportion of at-risk 
individuals in the population (older adults, people with chronic diseases), access to health 
services, availability of accurate diagnostic tests and resources to deal with severe and 
critical cases (ICU, mechanical ventilators, trained health care professionals).
A huge number of studies has helped clarify clinical profiles of SARS-CoV-2 infection, 
showing consistently that the presence of chronic morbidities such as diabetes mellitus (DM) 
and its associated diseases (obesity, hypertension, and cardiovascular disease) represent 
major risk factors for the severity and prognosis of the disease, in addition to advanced 
age. Accumulated evidence has caused a great concern in countries with high prevalence 
of these morbidities such as Brazil.
This text shows the picture of diabetes in Brazil, followed by epidemiological data and 
explanatory hypothesis for the association between diabetes and covid-19. We also 
emphasize how the burden of these two morbidities in a middle-income country may 
aggravate this pandemic scenario. 
The Actual Burden of Diabetes in Brazil
Brazil is a typical example of the alarming picture of DM in emergent societies for this 
century, being the fourth country with the largest number of diabetic people. In 2019, it was 
estimated that 16.8 million individuals, aged between 20 and 79 years had DM in Brazil, 
with projection of 55% increase until 20451. 
In the 1980s, a multicenter prevalence study, including 21,847 Brazilians aged between 30 and 
69 years submitted to oral glucose tolerance test, found that 7.6% had DM2. Most individuals 
had type 2 DM as occurs worldwide. We also found that almost half of individuals with DM 
were unaware of their condition. Even more impressive was the rate of undiagnosed DM 
registered in 2014 in the Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil—Brazilian 
Longitudinal Study of Adult Health) that found the same proportion in 15,000 participants 
of a non-representative sample3. 
A nationwide system of surveillance of risk and protective factors for chronic diseases 
by telephone survey (VIGITEL) in Brazil has yearly provided epidemiological data about 
non-communicable chronic diseases (NCCD) in individuals older than 18 years. A rate of 
5.5% of self-reported DM was described in 2016 and two years later it reached 8.0%4. Since 
previous studies have shown that half of diabetic Brazilians were undiagnosed, those 
frequencies were certainly underestimated. As expected, rates vary according to age group, 
but also according to schooling, being 23.1% for individuals older than 65 years and 15.2% 
for those with less than 8 years of total schooling4. 
Another aspect of DM in Brazil refers to its metabolic control. A nationwide cross-
sectional study, evaluating 5,750 patients with type 2 DM attending the public health 
care system between 2006 and 20115, reported a mean glycated hemoglobin (HbA1c) 
of 8.6% (SD 2.2). Targets (HbA1c <7%) recommended by scientific societies, such as 
the Brazilian Society of Diabetes, are achieved by a minority of patients even when 
a less strict target is considered. Only 48.5% of Brazilian patients sustain HbA1c 
< 8% which is poorer glycemic control than the observed in Europe and the USA. 
A multicenter study conducted in private health care system of Latin American 
countries showed that, among 878 Brazilian patients, approximately 40% had HbA1c 
levels higher than 7%6.
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As in other countries, in Brazil, NCCD are responsible for practically two thirds of the causes 
of death, being 5.2% due to DM7. Furthermore, DM represents an important risk factor for 
cardiovascular disease (CVD), which accounts for 31.3% of deaths in Brazil8.
This scenario of high DM prevalence (mainly in older adults and low socioeconomic stratus) 
associated with late diagnosis and poor glycemic control has a deleterious effect on the 
occurrence of long-term complications of the disease – macroangiopathy, retinopathy, 
nephropathy and neuropathy. Considering the covid-19 pandemic, global concerns on public 
health systems visibly increased, worsening the prognosis of diabetic individuals affected 
by the SARS-Cov-2 infection.
Diabetes and Covid-19: Epidemiological Evidence 
Since the first reports of covid-19 in Wuhan, China, high frequencies of diabetic individuals 
among hospitalized patients and those with fatal outcome have shown the importance 
of DM as a risk factor. Currently, type 2 DM is followed by other risky conditions such as 
advanced age, obesity, hypertension and CVD.
A Chinese study of 1,099 individuals with covid-19 showed that among 173 with severe 
disease 23.7% had hypertension, 16.2% DM, 5.8% coronary heart disease, and 2.3% 
cerebrovascular disease9. Another study with 140 patients admitted to the hospital reported 
similar rates, 30% of hypertension and 12% of DM10.
The most robust one conducted in China assessed a total of 44,672 cases of covid-1911. The 
fatality rate was 2.3%, which differs according to age and severity of manifestations. Death 
occurred in 14.8% of patients older than 80 years (208 out of 1,408), 8.0% between 70 and 
79 years (312 out of 3,918) and in 49.0% of severe cases (1,023 of 2,087). Among those who 
died and had chronic diseases, 10.5% had CVD, 7.3% DM, 6.3% chronic respiratory disease, 
6.0% hypertension, and 5.6% cancer. An analysis of 52 critical ill patients reinforced the 
role of age, male sex (67%) and previous chronic disease (40%) as risk factors12. Authors 
reported that non-survivors at 28 days (n = 32) neither presented difference in relation to 
the time from the onset of symptomatology, type of symptoms nor radiological changes 
until hospitalization. Non-survivors and survivors differed by age (64.6 versus 51.9 years, 
respectively) and proportion of concomitant chronic diseases (53% versus 20%).
Factors associated with mortality were also analyzed in 191 severe cases in China; 54 died 
and 137 discharged13. The strongest association was found with coronary heart disease (OR 
21.4, 95%CI 4.6-98.8), but also hypertension (OR 3.0, 95%CI 1.6-5.9), DM (OR 2.9, 95%CI % 
1.3-6.1), COPD (OR 5.4, 95%CI 1.0-30.4), and multiple organ failure (OR 6.1, 95%CI 3.5-10.8) 
which increase the risk of death. Altered circulating biomarkers (ferritin, interleukin 
6, D-dimer, troponin) were associated with fatal outcome. Considering the total of risk 
markers, independent predictors of mortality were older age, CVD, multiple organ failure 
and D-dimer concentration >1 mcg/mL13. Notably, DM and hypertension could have not 
appeared as independent predictors considering that they are mediators of cardiovascular 
events and mortality, which should imply underestimation of the effect of these diseases 
for the fatal outcomes13.
As the pandemic advanced to other continents, data from Europe and Americas have 
confirmed this worrying relationship between DM and covid-19 prognosis. In the Lombardy 
region of Italy, among 1,591 ICU patients affected between February and March 2020, 68% 
had at least one comorbidity, 49% systemic hypertension, 21% CVD, 17% type 2 DM, 8% 
cancer, and 4% COPD14.
In the USA, the Coronavirus Disease 2019–Associated Hospitalization Surveillance Network 
(COVID-NET) showed that 89.3% of 178 adults had one or more underlying morbidities; the 
most common was hypertension (49.7%), followed by obesity (48.3%), chronic lung disease 
(34.6%), DM (28.3%) and CVD (27.8%). In individuals aged between 18 and 49 years, obesity 
was the most frequent condition, followed by chronic lung disease (primarily asthma) 
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and DM while in those aged between 50 and 64 years the most frequent diseases were 
hypertension and DM15. Further report confirmed that age > 60 years with a BMI 30-34 kg/
m2 doubled the chance of being admitted to hospital (HR 2.0, p < 0.0001) and critical care 
(HR 1.8; p = 0.006) compared to age < 60 years with a BMI < 30 kg/m2 16. 
In Brazil, data from the Ministry of Health also identify DM and previous CVD as the 
comorbidities mostly associated with death in individuals affected by the SARS-Cov-2. 
DM and CVD can be seen as the same disease since atherosclerosis is present in the 
natural history of long-term DM. Also, hyperglycemia can firstly manifest during an acute 
cardiovascular event. 
The concern about the relationship between cardiometabolic diseases and covid-19 is not 
unprecedented. Previous studies have improved knowledge on the associations of DM and 
CVD with influenza epidemics, H1N1 or MERS17 and this knowledge supports researchers 
to provide clues to manage the current pandemic. 
The understanding of the biological plausibility for the association of DM and covid-19 might 
clarify underlying mechanisms, reinforcing possible causal relationships, thus enabling 
more effective prevention strategies to face viral epidemics. 
Advances in Plausibility of the Association between DM and Covid-19 Severity
Investigations on the biological plausibility of the association between DM and the severity 
of covid-19 are ongoing but it remains unclear. 
Adequate glycemic control reduces predisposition and improves prognosis against infections 
in people with DM. A recent study, including individuals without DM, showed that high 
levels of fasting plasma glucose were a predictor of poor outcomes and death in covid-19 
patients18. Direct role of the disturbance of glucose metabolism and its contribution to the 
covid-19 severity has to be shown. 
DM is a low-grade inflammation state, and a high-grade of systemic inflammation 
occurs in covid-19, reflected by elevations in inflammatory markers such as C-reactive 
protein, dimer-D and ferritin13. Therefore, DM and its associated diseases could provide 
a background to exacerbate inflammatory process contributing to the progression of 
covid-19 in diabetic individuals.
In the same context, the association of obesity with covid-19 could corroborate this 
hypothesis considering that the former is also a pro-inflammatory state and a risk factor 
for type 2 DM. Excessive adiposity produce cytokines and generates insulin resistance and 
endothelial dysfunction, an early event in atherogenesis. Reasons why obesity has been 
associated with covid-19 hospitalization and severity15, especially in people under 60 years 
of age16 are under discussion. As previously mentioned, atherosclerosis is the macrovascular 
complication of DM and its presence could contribute to understanding the increased 
covid-19 severity and mortality. In some studies, and also in Brazil (unpublished data), CVD 
has been considered the strongest predictor of severity and mortality due to SARS-Cov-2 
infection. The effect of cardiovascular causes of death on hospitalized patients, including 
myocarditis, arrhythmias, myocardial infarction and systemic thrombosis is highlighted 
in recent review17.
A possible deleterious role of medications to treat these morbidities was raised. 
Pathophysiological pathways of DM and hypertension were demonstrated to worsen 
SARS-Cov-2 infection19 and some medications mechanism of action were based on these 
pathways. Coronaviruses were able to bind to target cells through angiotensin-converting 
enzyme 2 (ACE2) receptor which is expressed in several tissues. Researchers documented 
that ECA2 is increased in individuals with type 1 and type 2 DM and that some medications 
can increase ACE2 expression, such as ACE inhibitors, angiotensin 2 receptor blockers (ARB), 
thiazolidinediones and ibuprofen. However, no evidence indicates potential adverse effects 
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of these agents on the prognosis of diabetic and hypertensive individuals with covid-19. 
Therefore, scientific societies such as the Brazilian Diabetes Society20 have not recommended 
the withdrawal of these drugs due to SARS-Cov-2 infection21,22.
FINAL CONSIDERATIONS
While advances in the knowledge of the relationship between DM and covid-19 occur, health 
professionals have experienced difficulties in clinical management and public health systems 
in the support of the heavy burden of these two morbidities in populations. Pathophysiological 
relationship must be well understood to plan preventive measures and/or to propose more 
effective therapeutic strategies. In this context, we could indicate some gaps regarding the 
severity of DM and SARS-Cov-2 infection that should be focused in future studies. It is possible 
that susceptibility and prognosis vary according to the type of DM, age, duration of illness, 
degree of glycemic control, presence of complications and medications in use. 
In summary, DM in individuals with covid-19 is more than the simple sum of two morbidities 
in prognostic terms. Understanding underlying mechanisms of this association are urgently 
necessary to face the current SARS-Cov-2, to propose in effective prevention through 
vaccination and pharmacological agents as well as to prepare the health care systems for 
future challenges. 
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